Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Jie ZhaoChawnshang Chang

Abstract

Hepatocellular carcinoma (HCC) is one of most common cancers worldwide, however, the treatment for advanced HCC remains unsatisfactory. We focused on the function of the androgen receptor (AR) in HCC and tried to find new treatment strategy based on antiandrogen enzalutamide (Enz). Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxicity in HCC cells with a lower BRCA1 expression, and suppressing the AR with either Enz or AR-shRNA could further increase the olaparib sensitivity to better suppress the HCC cell growth via a synergistic mechanism that may involve suppressing the expression of BRCA1 and other DNA damage response (DDR) genes. Mechanism studies revealed that Enz/AR signaling might transcriptionally regulate the miR-146a-5p expression via binding to the Androgen Response Elements on its 5' promoter region, which could then lead to suppress the homologous recombination-related BRCA1 expression via direct binding to the mRNA 3'UTR. Preclinical studies using an in vivo mouse model also demonstrated that combining Enz plus olaparib led to better suppression of the HCC progression. Together, these in vitro/in vivo data suggest that combining Enz and olaparib may help in the development of...Continue Reading

References

Dec 1, 1988·Journal of Clinical Gastroenterology·S Gupta, J Korula
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C GrimaldiJ Wils
Oct 29, 1999·Genes & Development·A J PierceM Jasin
May 27, 2004·World Journal of Gastroenterology : WJG·Pisit TangkijvanichYong Poovorawan
Aug 25, 2006·Nature Reviews. Cancer·Paraskevi A Farazi, Ronald A DePinho
Jan 31, 2007·Annals of the New York Academy of Sciences·Massimo Di MaioFrancesco Perrone
Apr 5, 2007·Nature Protocols·Peggy L Olive, Judit P Banáth
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Aug 28, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chian-Feng ChenYuh-Shan Jou
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Aug 28, 2012·Nature Genetics·Jian HuangZe-Guang Han
Sep 13, 2013·Cancer Discovery·William R PolkinghornCharles L Sawyers
May 31, 2014·BioMed Research International·Sheau-Fang YangYao-Tsung Yeh
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jun 10, 2015·Nature Reviews. Clinical Oncology·Josep M LlovetRichard S Finn
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Aug 31, 2017·Nature Communications·Mohammad AsimThomas Helleday
Mar 22, 2019·Wiley Interdisciplinary Reviews. RNA·Joseph R Iacona, Carol S Lutz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Australian Prescriber
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Marklie Munroe, Jill Kolesar
© 2021 Meta ULC. All rights reserved